Prolight Diagnostics AB (publ) has completed a directed share issue using an accelerated bookbuild. The directed share issue has been effected mainly with Swedish institutional and private investors and has provided Prolight with a capital injection of approximately SEK 55 million before transaction costs.
The subscription price was set at SEK 2.65 per share using an accelerated bookbuild, which represents a discount of around 4 per cent on the volume-weighted average price of the Prolight share on the NGM Nordic SME over the past 30 trading days.
Prolight, together with its technology partners, develops Point Of Care Testing (POCT) systems that are based on patented technology. POCT takes place outside the traditional hospital laboratory using small, mobile instruments on hospital wards, at healthcare centres, in intensive care units, etc., which enables testing to take place where the patient is, with rapid test results. This technology will enable healthcare providers to determine at an early stage of diagnosis which patients are in need of urgent care.
Advokatfirman Lindahl has assisted Prolight in raising capital in the capacity of legal adviser. Lindahl’s team was Johan Herrström, Carl-Johan Krusell and Pontus Söderberg.
